{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:22:37Z","timestamp":1759335757724},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title><jats:sec id=\"S0317167121001955_as1\"><jats:title>Background:<\/jats:title><jats:p>Migraine is a common primary headache disorder diagnosed in the emergency department (ED). This systematic review sought to compare the efficacy of sodium valproate (SV) to dopamine antagonists (DA) in relieving pain due to acute migraine.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001955_as2\"><jats:title>Methods:<\/jats:title><jats:p>Two research librarians helped create a search strategy including Embase, Ovid Medline, and the Cochrane Database of Clinical Trials from inception to June 1, 2020, updated May 19, 2021. Two investigators identified randomized control trials (RCTs) including adult patients with acute migraine presenting to the ED or acute clinical setting comparing SV to a DA with the aim of relieving pain. Primary outcome was headache relief at 1 hour from treatment. Secondary outcomes included pain relief at 24 hours, relief of associated symptoms (e.g. nausea, photo-\/phonophobia, etc.), and need for rescue analgesia. Meta-analysis was performed and presented as odds ratios.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001955_as3\"><jats:title>Results:<\/jats:title><jats:p>Four RCTs with 470 patients were identified from an initial pool of 454 titles. Two studies compared SV to a DA alone and two compared SV to a DA plus one other agent (sumatriptan or dihydroergotamine). Three studies were included for meta-analysis. Pain relief had a pooled odds ratio of 1.14 at 1 hour and 0.42 at 24 hours. Three articles reporting the need for rescue analgesia had pooled odds ratio of 2.76.<\/jats:p><\/jats:sec><jats:sec id=\"S0317167121001955_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>Sodium valproate is not more effective than DA at reducing migraine headache pain at 1 hour and less effective at 24 hours. Dopamine antagonists should be used over SV for the management of patients with acute migraine.<\/jats:p><\/jats:sec>","DOI":"10.1017\/cjn.2021.195","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T09:42:35Z","timestamp":1628761355000},"page":"688-695","source":"Crossref","is-referenced-by-count":5,"title":["Sodium Valproate Versus Dopamine Antagonists for Acute Migraine in the Emergency Department: A Systematic Review"],"prefix":"10.1017","volume":"49","author":[{"given":"J. Alexander","family":"Viau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cortel-LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"S0317167121001955_ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120229"},{"key":"S0317167121001955_ref15","unstructured":"15. Mylan Pharmaceuticals ULC. Product monograph - PrMylan-Divalproex Divalproex Sodium Enteric-Coated Tablets (125 Mg, 250 Mg, 500 Mg) Mfr. Std.; 2018. Website. https:\/\/pdf.hres.ca\/dpd_pm\/00047047.PDF"},{"key":"S0317167121001955_ref19","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2016.12.4.468"},{"key":"S0317167121001955_ref36","first-page":"633","article-title":"Intravenous valproate versus subcutaneous sumatriptan in acute migraine attack","volume":"53","author":"Ghaderibarmi","year":"2015","journal-title":"Acta Med Iran"},{"key":"S0317167121001955_ref3","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100041950"},{"key":"S0317167121001955_ref11","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","volume":"6","author":"Linde","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"S0317167121001955_ref33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.01191.x"},{"key":"S0317167121001955_ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0993-0"},{"key":"S0317167121001955_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"S0317167121001955_ref35","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13325"},{"key":"S0317167121001955_ref38","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.3_Part_1.447"},{"key":"S0317167121001955_ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"S0317167121001955_ref34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/14656566.2018.1516205","article-title":"Treating status migrainosus in the emergency setting: what is the best strategy?","volume":"19","author":"L\u00e1szl\u00f3","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"S0317167121001955_ref13","first-page":"783","article-title":"Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study","volume":"17","author":"Hesami","year":"2018","journal-title":"Iran J Pharm Res"},{"key":"S0317167121001955_ref31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000223"},{"key":"S0317167121001955_ref16","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","article-title":"The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?","volume":"64","author":"Rosenberg","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"S0317167121001955_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"S0317167121001955_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0320-4"},{"key":"S0317167121001955_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-012-0482-1"},{"key":"S0317167121001955_ref14","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666170329094419"},{"key":"S0317167121001955_ref10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1992.1202081.x"},{"key":"S0317167121001955_ref30","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2003.195"},{"key":"S0317167121001955_ref27","unstructured":"27. Review Manager (Revman) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"S0317167121001955_ref24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0333102414535997","article-title":"Canadian headache society systematic review and recommendations on the treatment of migraine pain in emergency settings","volume":"35","author":"Orr","year":"2015","journal-title":"Cephalalgia"},{"key":"S0317167121001955_ref37","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550120097022"},{"key":"S0317167121001955_ref1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100010738"},{"key":"S0317167121001955_ref28","article-title":"A revised tool for assessing risk of bias in randomized trials (RoB 2.0). Cochrane methods","volume":"10","author":"Higgins","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"S0317167121001955_ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828967"},{"key":"S0317167121001955_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/23.5.1020"},{"key":"S0317167121001955_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2012.10.014"},{"key":"S0317167121001955_ref18","doi-asserted-by":"publisher","DOI":"10.15441\/ceem.16.199"},{"key":"S0317167121001955_ref21","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"S0317167121001955_ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12915"},{"key":"S0317167121001955_ref4","first-page":"10","article-title":"Prevalence of migraine in the Canadian household population","volume":"25","author":"Ramage-Morin","year":"2014","journal-title":"Health Rep"},{"key":"S0317167121001955_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30085-1"},{"key":"S0317167121001955_ref12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/ijp.IJP_457_18","article-title":"Low\u2013dose sodium valproate versus low\u2013dose propranolol in prophylaxis of common migraine headache: a randomized, prospective, parallel, open\u2013label study","volume":"51","author":"Dakhale","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"S0317167121001955_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"S0317167121001955_ref7","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167121001955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:53:33Z","timestamp":1662537213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167121001955\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0317167121001955"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2021.195","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}